SCHEMBL6489175

SCHEMBL6489175

CC/C(C(=O)O)=C(/C)c1ccc(-c2ccc(Cl)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
ERCC5 P28715 1/20 0.42
FEN1 P39748 1/20 0.42
CYP19A1 P11511 2/20 0.41
POLB P06746 2/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
CTDSP1 Q9GZU7 1/20 0.41
MMP2 P08253 2/20 0.40
MMP9 P14780 2/20 0.40
MMP8 P22894 1/20 0.40
RXRA P19793 1/20 0.40
RXRB P28702 1/20 0.40
CES2 O00748 2/20 0.39
CES1 P23141 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6489191 1.00 MAPT (0.43) MAPTSMN1; SMN2L3MBTL1ALOX15TSHR
SCHEMBL9518984 0.95 ALOX15 (0.47) MAPTSMN1; SMN2L3MBTL1ALOX15TSHR
SCHEMBL9518997 0.95 ALOX15 (0.47) MAPTSMN1; SMN2L3MBTL1ALOX15TSHR
SCHEMBL23934177 0.79 ALDH1A1 (0.47) ALOX15TSHRERCC5FEN1CYP19A1
SCHEMBL5491615 0.78 CES1 (0.50) MAPTSMN1; SMN2L3MBTL1ALOX15TSHR
SCHEMBL18143864 0.77 TPMT (0.47) MAPTERCC5FEN1ALDH1A1GAA
SCHEMBL18143857 0.77 TPMT (0.47) MAPTERCC5FEN1ALDH1A1GAA
SCHEMBL6497142 0.77 HTT (0.46) MAPTSMN1; SMN2POLBKDM4EALDH1A1
SCHEMBL6497138 0.77 HTT (0.46) MAPTSMN1; SMN2POLBKDM4EALDH1A1
SCHEMBL6381408 0.75 PTPN1 (0.51) MAPTALDH1A1MMP2MMP8CES2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6867218-B2 Compounds, their preparation and use NOVO NORDISK A/S (DK) 2005-03-15 US disclosed
US-20030195200-A1 Compounds, their preparation and use VTVX HOLDINGS II LLC 2003-10-16 US disclosed
US-6555577-B1 For treatment and/or prevention of conditions mediated by the Peroxisome Proliferator-Activated Receptors (PPAR), such as diabetes and/or obesity; 3-(4-(3-Biphenyl-4-yl-but-2-enyloxy)-phenyl)-2-butoxy-propionic acid for example NOVO NORDISK A/S (DE) 2003-04-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195200-A1 Compounds, their preparation and use PPARG, PPARA, PPARD MAPT 3845/4885SMN1; SMN2 3127/4885L3MBTL1 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.